BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 10219339)

  • 1. Gonadal function in young patients successfully treated for Hodgkin disease.
    Papadakis V; Vlachopapadopoulou E; Van Syckle K; Ganshaw L; Kalmanti M; Tan C; Sklar C
    Med Pediatr Oncol; 1999 May; 32(5):366-72. PubMed ID: 10219339
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gonadal function and fertility in survivors after Hodgkin lymphoma treatment within the German Hodgkin Study Group HD13 to HD15 trials.
    Behringer K; Mueller H; Goergen H; Thielen I; Eibl AD; Stumpf V; Wessels C; Wiehlpütz M; Rosenbrock J; Halbsguth T; Reiners KS; Schober T; Renno JH; von Wolff M; van der Ven K; Kuehr M; Fuchs M; Diehl V; Engert A; Borchmann P
    J Clin Oncol; 2013 Jan; 31(2):231-9. PubMed ID: 23150709
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of etoposide on testicular function in boys treated for Hodgkin's disease.
    Gerres L; Brämswig JH; Schlegel W; Jürgens H; Schellong G
    Cancer; 1998 Nov; 83(10):2217-22. PubMed ID: 9827728
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Changes in gonadal function in post-pubertal male survivors of acute lymphoblastic leukemia and Hodgkin's disease].
    Soriano Guillén L; Muñoz Calvo MT; Pozo Román J; Contra Gómez T; Buño Soto M; Argente Oliver J
    An Esp Pediatr; 2000 Oct; 53(4):318-23. PubMed ID: 11083980
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Testicular function after OPA/COMP chemotherapy without procarbazine in boys with Hodgkin's disease. Results in 25 patients of the DAL-HD-85 study].
    Hassel JU; Brämswig JH; Schlegel W; Schellong G
    Klin Padiatr; 1991; 203(4):268-72. PubMed ID: 1942933
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decreasing the number of MOPP courses reduces gonadal damage in survivors of childhood Hodgkin disease.
    van den Berg H; Furstner F; van den Bos C; Behrendt H
    Pediatr Blood Cancer; 2004 Mar; 42(3):210-5. PubMed ID: 14752856
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gonadal status and reproductive function following treatment for Hodgkin's disease in childhood: the Stanford experience.
    Ortin TT; Shostak CA; Donaldson SS
    Int J Radiat Oncol Biol Phys; 1990 Oct; 19(4):873-80. PubMed ID: 2211255
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ovarian function after cancer treatment in young women affected by Hodgkin disease (HD).
    Giuseppe L; Attilio G; Edoardo DN; Loredana G; Cristina L; Vincenzo L
    Hematology; 2007 Apr; 12(2):141-7. PubMed ID: 17454195
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gonadal function following ABVD therapy for Hodgkin's disease.
    Kulkarni SS; Sastry PS; Saikia TK; Parikh PM; Gopal R; Advani SH
    Am J Clin Oncol; 1997 Aug; 20(4):354-7. PubMed ID: 9256888
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term gonadal dysfunction and its impact on bone mineralization in patients following COPP/ABVD chemotherapy for Hodgkin's disease.
    Kreuser ED; Felsenberg D; Behles C; Seibt-Jung H; Mielcarek M; Diehl V; Dahmen E; Thiel E
    Ann Oncol; 1992 Sep; 3 Suppl 4():105-10. PubMed ID: 1280463
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Decreased serum inhibin B/FSH ratio as a marker of Sertoli cell function in male survivors after chemotherapy in childhood and adolescence.
    Bordallo MA; Guimarães MM; Pessoa CH; Carriço MK; Dimetz T; Gazolla HM; Dobbin J; Castilho IA
    J Pediatr Endocrinol Metab; 2004 Jun; 17(6):879-87. PubMed ID: 15270406
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term gonadal toxicity after therapy for Hodgkin's and non-Hodgkin's lymphoma.
    Bokemeyer C; Schmoll HJ; van Rhee J; Kuczyk M; Schuppert F; Poliwoda H
    Ann Hematol; 1994 Mar; 68(3):105-10. PubMed ID: 8167175
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced Hodgkin disease.
    Montoto S; Camós M; López-Guillermo A; Bosch F; Cervantes F; Blandé J; Esteve J; Cobo F; Nomdedeu B; Campo E; Montserrat E
    Cancer; 2000 May; 88(9):2142-8. PubMed ID: 10813727
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibin A concentrations in the sera of young women during and after chemotherapy for lymphoma: correlation with ovarian toxicity.
    Blumenfeld Z; Ritter M; Shen-Orr Z; Shariki K; Ben-Shahar M; Haim N
    Am J Reprod Immunol; 1998 Jan; 39(1):33-40. PubMed ID: 9458932
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of different cumulative doses of chemotherapy on testicular function. Results in 75 patients treated for Hodgkin's disease during childhood or adolescence.
    Brämswig JH; Heimes U; Heiermann E; Schlegel W; Nieschlag E; Schellong G
    Cancer; 1990 Mar; 65(6):1298-302. PubMed ID: 2106384
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gonadal function following chemotherapy for childhood Hodgkin's disease.
    Mackie EJ; Radford M; Shalet SM
    Med Pediatr Oncol; 1996 Aug; 27(2):74-8. PubMed ID: 8649323
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reproductive and endocrine gonadal capacity in patients treated with COPP chemotherapy for Hodgkin's disease.
    Kreuser ED; Xiros N; Hetzel WD; Heimpel H
    J Cancer Res Clin Oncol; 1987; 113(3):260-6. PubMed ID: 3108263
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-Mullerian hormone is a sensitive serum marker for gonadal function in women treated for Hodgkin's lymphoma during childhood.
    van Beek RD; van den Heuvel-Eibrink MM; Laven JS; de Jong FH; Themmen AP; Hakvoort-Cammel FG; van den Bos C; van den Berg H; Pieters R; de Muinck Keizer-Schrama SM
    J Clin Endocrinol Metab; 2007 Oct; 92(10):3869-74. PubMed ID: 17726078
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of children and adolescents with Hodgkin lymphoma without radiotherapy for patients in complete remission after chemotherapy: final results of the multinational trial GPOH-HD95.
    Dörffel W; Rühl U; Lüders H; Claviez A; Albrecht M; Bökkerink J; Holte H; Karlen J; Mann G; Marciniak H; Niggli F; Schmiegelow K; Schwarze EW; Pötter R; Wickmann L; Schellong G
    J Clin Oncol; 2013 Apr; 31(12):1562-8. PubMed ID: 23509321
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage hodgkin's lymphoma: final analysis of the HD12 trial of the German Hodgkin Study Group.
    Borchmann P; Haverkamp H; Diehl V; Cerny T; Markova J; Ho AD; Eich HT; Mueller-Hermelink HK; Kanz L; Greil R; Rank A; Paulus U; Smardova L; Huber C; Dörken B; Nerl C; Krause SW; Mueller RP; Fuchs M; Engert A
    J Clin Oncol; 2011 Nov; 29(32):4234-42. PubMed ID: 21990399
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.